Evidence map›Paper›PMID 37181949›Full record

ArticleBreast cancer : basic and clinical research2023

Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.

Adeel Haq, Tyler J Fraum, Yu Tao, Farrokh Dehdashti, Maverick LeBlanc, Mark J Hoegger, Jingqin Luo, Katherine Weilbaecher, Lindsay L Peterson

Open access · goldAbstract read
In one paragraph

Article in Breast cancer : basic and clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. TheInternational journal of molecular sciences · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Adeel HaqDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Tyler J FraumDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Yu TaoDepartment of Surgery, Washington University in St. Louis, St. Louis, MO, USA.
Farrokh DehdashtiDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Maverick LeBlancDepartment of Radiology, Ochsner Medical Center, Jefferson, LA, USA.
Mark J HoeggerDepartment of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Jingqin LuoDepartment of Surgery, Washington University in St. Louis, St. Louis, MO, USA.
Katherine WeilbaecherAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Lindsay L PetersonAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Washington University in St. Louis · USAlvin J. Siteman Cancer CenterOchsner Medical Center · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

Background: Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis. Objectives: To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS. Design: Retrospective analysis. Methods: We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed. Results: There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant ( Conclusion: The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.

Indexed as

computed tomographydistant metastatic diseasehepatic fat contentHepatic steatosisliver metastasesmetastatic breast cancer

Identifiers

PMID37181949
PMCPMC10170590
OpenAlexW4368241397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.